Opium (Opioid) Addiction - Pipeline Review, H2 2018

Publisher Name :
Date: 11-Sep-2018
No. of pages: 121
Inquire Before Buying

Opium (Opioid) Addiction - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Opium (Opioid) Addiction - Pipeline Review, H2 2018, provides an overview of the Opium (Opioid) Addiction (Central Nervous System) pipeline landscape.

Opioid Addiction develops after using opioids regularly for a period of time. Prolonged use of opiates can lead to nerve damage within the brain that causes cells to stop producing endogenous opiates (natural painkillers known as endorphins). This can lead to an inability for the body to stop pain because there are no endorphins to mask the pain initially. The degeneration of the nerve cells that reduce pain can lead to a physical dependence on opiates as an external supply source. Signs and symptoms include increased general anxiety, euphoria, psychosis, depression, high blood pressure, decreased appetite, physical agitation, difficulty sleeping and pain in the bones. The predisposing factors include age, a personal history of substance abuse, and family history of substance abuse, cigarette dependency and psychologic stress.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Opium (Opioid) Addiction - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Opium (Opioid) Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Opium (Opioid) Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Opium (Opioid) Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 4, 6, 2, 18, 3 and 1 respectively. Similarly, the Universities portfolio in Phase II and Preclinical stages comprises 1 and 6 molecules, respectively.

Opium (Opioid) Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Opium (Opioid) Addiction (Central Nervous System).

- The pipeline guide reviews pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Opium (Opioid) Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Opium (Opioid) Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Opium (Opioid) Addiction (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Opium (Opioid) Addiction (Central Nervous System).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Opium (Opioid) Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Opium (Opioid) Addiction - Pipeline Review, H2 2018

Table of Contents
Table of Contents 2
Introduction 5
Opium (Opioid) Addiction - Overview 6
Opium (Opioid) Addiction - Therapeutics Development 7
Opium (Opioid) Addiction - Therapeutics Assessment 16
Opium (Opioid) Addiction - Companies Involved in Therapeutics Development 24
Opium (Opioid) Addiction - Drug Profiles 34
Opium (Opioid) Addiction - Dormant Projects 106
Opium (Opioid) Addiction - Discontinued Products 107
Opium (Opioid) Addiction - Product Development Milestones 108
Appendix 115

List of Tables
Number of Products under Development for Opium (Opioid) Addiction, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Companies, H2 2018 (Contd..1), H2 2018
Products under Development by Companies, H2 2018 (Contd..2), H2 2018
Products under Development by Universities/Institutes, H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Opium (Opioid) Addiction - Pipeline by Adapt Pharma Ltd, H2 2018
Opium (Opioid) Addiction - Pipeline by Addex Therapeutics Ltd, H2 2018
Opium (Opioid) Addiction - Pipeline by Aoxing Pharmaceutical Company Inc, H2 2018
Opium (Opioid) Addiction - Pipeline by BioCorRx Inc, H2 2018
Opium (Opioid) Addiction - Pipeline by BioDelivery Sciences International Inc, H2 2018
Opium (Opioid) Addiction - Pipeline by Camurus AB, H2 2018
Opium (Opioid) Addiction - Pipeline by Fab'entech SA, H2 2018
Opium (Opioid) Addiction - Pipeline by Indivior Plc, H2 2018
Opium (Opioid) Addiction - Pipeline by Insys Therapeutics Inc, H2 2018
Opium (Opioid) Addiction - Pipeline by iX Biopharma Ltd, H2 2018
Opium (Opioid) Addiction - Pipeline by Novartis AG, H2 2018
Opium (Opioid) Addiction - Pipeline by Omeros Corp, H2 2018
Opium (Opioid) Addiction - Pipeline by Opiant Pharmaceuticals Inc, H2 2018
Opium (Opioid) Addiction - Pipeline by Orexo AB, H2 2018
Opium (Opioid) Addiction - Pipeline by Pfizer Inc, H2 2018
Opium (Opioid) Addiction - Pipeline by Relmada Therapeutics Inc, H2 2018
Opium (Opioid) Addiction - Pipeline by Serina Therapeutics Inc, H2 2018
Opium (Opioid) Addiction - Pipeline by Syntropharma Ltd, H2 2018
Opium (Opioid) Addiction - Pipeline by Titan Pharmaceuticals Inc, H2 2018
Opium (Opioid) Addiction - Pipeline by Zynerba Pharmaceuticals Inc, H2 2018
Opium (Opioid) Addiction - Dormant Projects, H2 2018
Opium (Opioid) Addiction - Discontinued Products, H2 2018

List of Figures
Number of Products under Development for Opium (Opioid) Addiction, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Molecule Types, H2 2018
Number of Products by Stage and Molecule Types, H2 2018
  • Global CNS Therapeutics Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 18-Sep-2018        Price: US 3480 Onwards        Pages: 136
    Central nervous system (CNS) disease is a broad category of conditions in which the brain does not function as it should, limiting health and the ability to function. The condition may be an inherited metabolic disorder; the result of damage from an infection, a degenerative condition, stroke, a brain tumor or other problem; or arise from unknown or multiple factors. Movement disorders such as Parkinson's disease, dystonia, and essential tremor are central nervous system conditions. What they ha......
  • Depression - Pipeline Review, H2 2018
    Published: 11-Sep-2018        Price: US 2000 Onwards        Pages: 504
    Depression - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Depression - Pipeline Review, H2 2018, provides an overview of the Depression (Central Nervous System) pipeline landscape. Depression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anx......
  • Friedreich Ataxia - Pipeline Review, H2 2018
    Published: 11-Sep-2018        Price: US 2000 Onwards        Pages: 91
    Friedreich Ataxia - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Friedreich Ataxia - Pipeline Review, H2 2018, provides an overview of the Friedreich Ataxia (Central Nervous System) pipeline landscape. Friedreich's ataxia (FA) is a neuromuscular disease that mainly affects the nervous system and the heart. FA is a hereditary disease, caused by a defective gene that can be passed down th......
  • Dyskinesia - Pipeline Review, H2 2018
    Published: 11-Sep-2018        Price: US 2000 Onwards        Pages: 182
    Dyskinesia - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Dyskinesia - Pipeline Review, H2 2018, provides an overview of the Dyskinesia (Central Nervous System) pipeline landscape. Dyskinesia refers to the involuntary nature of muscular movements or the difficulty in performing voluntary muscular movement. Symptoms include facial grimacing, finger movement, jaw swinging, repetitive chew......
  • Anesthetic Effect - Pipeline Review, H2 2018
    Published: 11-Sep-2018        Price: US 2000 Onwards        Pages: 83
    Anesthetic Effect - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Anesthetic Effect - Pipeline Review, H2 2018, provides an overview of the Anesthetic Effect (Central Nervous System) pipeline landscape. Anesthetic effect causes a loss of consciousness. The factors that can increase risk of complications include smoking, obstructive sleep apnea, obesity, high blood pressure, history of ad......
  • Mild Cognitive Impairment - Pipeline Review, H2 2018
    Published: 11-Sep-2018        Price: US 2000 Onwards        Pages: 106
    Mild Cognitive Impairment - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Mild Cognitive Impairment - Pipeline Review, H2 2018, provides an overview of the Mild Cognitive Impairment (Central Nervous System) pipeline landscape. Mild cognitive impairment (MCI) is a condition involving problems with cognitive function (such as thinking, knowing and remembering). MCI is an intermediate stage......
  • Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2018
    Published: 11-Sep-2018        Price: US 2000 Onwards        Pages: 113
    Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Neuromyelitis Optica (Devic's Syndrome) - Pipeline Review, H2 2018, provides an overview of the Neuromyelitis Optica (Devic's Syndrome) (Central Nervous System) pipeline landscape. Neuromyelitis optica (NMO), also known as Devic's disease, is an uncommon neurological condition caused by disease or dam......
  • Global Spinal Cord Partnering 2012 to 2018
    Published: 01-Sep-2018        Price: US 1995 Onwards        Pages: 150
    "Delivery of this report will take 1-3 days after purchase." The Global Spinal Cord Partnering Terms and Agreements since 2012 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals - Top deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type The report provides understanding a......
  • Global Neuropathy Partnering 2012 to 2018
    Published: 01-Sep-2018        Price: US 1995 Onwards        Pages: 150
    "Delivery of this report will take 1-3 days after purchase." The Global Neuropathy Partnering Terms and Agreements since 2012 report provides understanding and access to partnering deals and agreements entered into by the world's leading healthcare companies. - Trends in partnering deals - Top deals by value - Deals listed by company A-Z, industry sector, stage of development, technology type The report provides understanding an......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs